Efficacy of ibandronate: a long term confirmation

Di Munno, Ombretta and Delle Sedie, Andrea (2010) Efficacy of ibandronate: a long term confirmation. Clinical cases in mineral and bone metabolism, 7 (1). pp. 23-26. ISSN 1971-3266

portiere.php.pdf - Published Version

Download (891kB)


Data deriving from randomized clinical trials, observational studies and meta-analyses, including treatment regimens unlicensed for use in clinical practice, clearly support that 150 mg oncemonthly oral and 3 mg quarterly i.v. doses of ibandronate are associated with efficacy, safety and tolerability; notably both these marketed regimens, which largely correspond to ACE ≥10.8 mg, may in addition provide a significant efficacy on non-vertebral and clinical fracture (Fx) efficacy. The MOBILE and the DIVA LTE studies confirmed a sustained efficacy of monthly oral and quarterly i.v. regimens respectively, over 5 years. Furthermore, improved adherence rates with monthly ibandronate, deriving from studies evaluating large prescription databases, promise to enhance fracture protection and decrease the social and economic burden of postmenopausal osteoporosis

Item Type: Article
Uncontrolled Keywords: Ibandronate, bisphosphonates, osteoporosis, long-term efficacy, fracture.
Subjects: 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 611 Anatomia; Citologia; Istologia umana > 611.7 Sistema muscoloscheletrico, tegumento
Depositing User: Danilo Dezzi
Date Deposited: 14 Jan 2014 10:40
Last Modified: 14 Jan 2014 10:40
URI: http://eprints.bice.rm.cnr.it/id/eprint/5587

Actions (login required)

View Item View Item